Health
Sanofi Plans €5 Billion Buyback, Sees Higher Profit Growth
- EPS seen increasing by low double-digit percentage in 2025
- Beyfortus tops sales estimates in quarter, Dupixent misses
This article is for subscribers only.
Sanofi said it will repurchase €5 billion ($5.2 billion) of stock and grow profits faster this year as the drugmaker pivots away from consumer health to focus on fast-growing drugs like its RSV shot.
Earnings per share, excluding some items, are likely to increase by a low double-digit percentage at constant currencies in 2025, compared with 4.1% growth last year, the French company said in a statement Thursday.